- CSL (ASX:CSL) publishes Corporate Responsibility Report 2010

The report details the company's performance across its key corporate responsibility priority areas for the period 1 July 2009 & 30 June 2010
Feb 2, 2011 8:03 AM ET

 (3BLMedia/theCSRfeed) February 2, 2011 - CSL Limited has published its second Corporate Responsibility Report - Our Corporate Responsibility 2010 - available at

The report details CSL’s performance across its key corporate responsibility priority areas for the period 1 July 2009 and 30 June 2010. These priority areas include the Company’s research into new and improved medicines, ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for employees, behaving responsibly in the global marketplace, providing charitable support for communities in need around the world and minimising the environmental impacts of its operations.

Highlights and statistics include:

  • Continued investment of over A$300m in the research and development of protein-based medicines for the prevention and treatment of rare and serious human illnesses.

  • Opening of a state-of-the-art plasma testing laboratory in the US.

  • More than A$4 billion in direct value distributed to local economies for the second successive year.

  • Another successful biennial employee opinion survey, with an 83% completion rate and 80% of the indicators rated as an area of strength or best practice.

  • Improvements in health and safety performance, including a 16% reduction in the medical treatment injury frequency rate.

  • A total community investment of A$26 million providing important support to patient, biomedical and local communities.

  • Achieving a reduction in environmental impact per unit of production across all reported indicators, including a 20% reduction in water consumption for vaccine production.

  • The conclusion of an enterprise-wide climate change risk assessment confirming CSL’s exposure to climate change risks as low over the next 25 years.

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the US, CSL has over 10,000 employees working in more than 20 countries.

Please provide feedback on CSL’s Our Corporate Responsibility 2010 Report at: